- Aurobindo Pharma‘s net income for the third quarter was 8.46 billion rupees.
- Net income decreased by 9.6% compared to the same period last year.
- This net income was below the estimated 8.93 billion rupees.
- Total costs for the company reached 69.38 billion rupees during the quarter.
- Employee benefits expenses amounted to 11.32 billion rupees, slightly higher than the estimated 11 billion rupees.
- Finance costs were reported at 1.18 billion rupees, exceeding the estimate of 904.7 million rupees.
- The company earned 1.57 billion rupees from other income sources.
- Market sentiment includes 21 buy recommendations, 4 hold recommendations, and 4 sell recommendations.
“`
A look at Aurobindo Pharma Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Aurobindo Pharma presents a positive long-term outlook. With a strong value score of 4, the company is considered to be undervalued compared to its peers. This indicates potential for future growth in stock price. Additionally, Aurobindo Pharma scores well in resilience with a score of 4, suggesting that the company has a solid financial standing and ability to weather market uncertainties.
On the growth front, Aurobindo Pharma has been rated a score of 3, indicating moderate growth prospects. The company’s momentum score of 3 implies that it has stable market momentum. While the dividend score stands at 3, reflecting a moderate dividend payout to shareholders. Overall, Aurobindo Pharma‘s strong value and resilience scores position it well for long-term success in the pharmaceutical industry.
**Summary:**
Aurobindo Pharma Limited is a pharmaceutical company that specializes in manufacturing and marketing oral and sterile antibiotics, antibacterials, anti-ulcerants, and other generic basic drugs. Their product range includes semi-synthetic penicillin drugs like ampicillin and amoxycillin, as well as antibiotics such as cloxacillin and dicloxacillin. Formulations like astemizole, domperidone, and omeprazole are also produced by the company.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
